Shares of J&J rose about 1% Tuesday, shaking off their premarket declines.
Get this delivered to your inbox, and more info about our products and services.
Leerink analysts lifted J&J shares to a buy equivalent from hold on Wednesday, citing the company's slate of new drugs.
Every weekday, the Investing Club releases the Homestretch; an actionable afternoon update just in time for the last hour of…
Morgan Stanley's price target implies that shares of Johnson & Johnson could rise another 17%.
Johnson & Johnson beats Q2 2026 Wall Street estimates and raises full-year guidance as sales top $25B, driven by oncology and…
JPMorgan sees shares of Ultragenyx Pharmaceutical soaring more than 200% from current prices.
Johnson & Johnson (NYSE: JNJ) shares are edging higher on Friday as investors digest two major biotech pipeline moves.
